ACHIEVEMENTS

October 2021

OncoStars Development Programme

Mantis Therapeutics was accepted into the next round of the highly competitive OncoStars programme.

September 2021

Patent approved in the United States

Mantis Therapeutics has received approval of a US patent protecting the intellectual property concerning our innovative anti-cancer immunotherapy.

September 2021

New labspace acquired

Mantis Therapeutics acquired new laboratorium space at the Bio Science Park in Leiden. In this environment directed towards innovation we will further develop our innovative therapy and grow as a company.

June 2021

OncoStars Action

Mantis Therapeutics was one of 10 companies, and the only non-UK company, invited to join in the OncoStars programme of Cancer Research UK.

December 2020

Patent approved in Europe

Mantis Therapeutics has received approval of an EU patent protecting the intellectual property concerning our innovative anti-cancer immunotherapy.

October 2019

Dutch Trading Mission

Mantis Therapeutics was invited to join the Dutch king and queen on a trading mission to India. Indian hospital directors expressed their interest in collaborating in the development of BaCure.

June 2019

Eureka Globalstars Grant

Mantis Therapeutics received a Eureka Globalstars Grant for the development of a Drug Delivery Platform in collaboration with a relevant Indian partner.